Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Avadel Pharmaceuticals Plc (AVDL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 175,250
  • Shares Outstanding, K 36,740
  • Annual Sales, $ 173,250 K
  • Annual Income, $ 68,270 K
  • 36-Month Beta 1.80
  • Price/Sales 1.04
  • Price/Cash Flow 10.92
  • Price/Book 2.29

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.53
  • Number of Estimates 1
  • High Estimate -0.53
  • Low Estimate -0.53
  • Prior Year 0.09
  • Growth Rate Est. (year over year) -688.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.66 +2.36%
on 08/07/18
7.03 -32.15%
on 07/17/18
-2.10 (-30.57%)
since 07/16/18
3-Month
4.66 +2.36%
on 08/07/18
7.97 -40.15%
on 06/15/18
-2.13 (-30.87%)
since 05/16/18
52-Week
4.66 +2.36%
on 08/07/18
11.93 -60.02%
on 01/25/18
-4.04 (-45.86%)
since 08/16/17

Most Recent Stories

More News
Avadel Pharmaceuticals PLC Sponsored ADR to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Avadel Pharmaceuticals PLC Sponsored ADR (NASDAQ: ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 10:00...

AVDL : 4.77 (-2.45%)
Avadel Pharmaceuticals to Report Second Quarter 2018 Results

Avadel Pharmaceuticals plc (Nasdaq:AVDL), today announced it will report its second quarter 2018 financial results on Tuesday, August 7, 2018, before the market open. A conference call to discuss these...

AVDL : 4.77 (-2.45%)
Jazz Pharmaceuticals' sNDA for Xyrem Gets Priority Review

Jazz Pharmaceuticals' (JAZZ) label expansion application for Xyrem in pediatric patients gets priority review from the FDA.

AGLE : 9.22 (+0.99%)
AVDL : 4.77 (-2.45%)
JAZZ : 173.12 (-0.49%)
ANIP : 55.82 (-0.32%)
Jaguar Health Appoints Senior Commercial Pharmaceutical Executive Greg Divis to Board of Directors

SAN FRANCISCO, CA / ACCESSWIRE / June 18, 2018 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage natural-products pharmaceutical company focused on developing novel,...

AVDL : 4.77 (-2.45%)
JAGX : 0.92 (+1.10%)
AMAG : 24.45 (-1.41%)
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

Avadel Pharmaceuticals plc (Nasdaq:AVDL), "Avadel" or the "Company," today announced that management will present at two upcoming investor conferences:

AVDL : 4.77 (-2.45%)
Free Technical Insights on CASI Pharma and Three Other Biotech Stocks

Stock Research Monitor: AVDL, CDMO, and BPMC

AVDL : 4.77 (-2.45%)
BPMC : 70.73 (+0.71%)
Analysis: Positioning to Benefit within Avadel Pharmaceuticals, Abeona Therapeutics, BanColombia S.A, Aercap Holdings N.V, Kite Realty Group Trust, and Credicorp -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Avadel Pharmaceuticals PLC....

KRG : 17.34 (+1.88%)
BAP : 222.60 (+0.16%)
AVDL : 4.77 (-2.45%)
ABEO : 13.70 (+4.98%)
CIB : 44.72 (+3.04%)
AER : 56.63 (+0.78%)
Avadel to Present Late-Breaker Data and Product Theater Forum at the 2018 American Urological Association Annual Meeting

Data demonstrates extended first uninterrupted sleep period in elderly patients

AVDL : 4.77 (-2.45%)
Avadel Launches NOCTIVA(TM), the First and Only FDA-Approved Treatment for Nocturia Due to Nocturnal Polyuria

Avadel Pharmaceuticals plc (Nasdaq:AVDL) today announced the launch of NOCTIVA(TM) (desmopressin acetate), an emulsified microdose Nasal Spray. NOCTIVA is the first and only FDA-approved treatment proven...

AVDL : 4.77 (-2.45%)
Avadel Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care Conference

Avadel Pharmaceuticals plc (Nasdaq:AVDL), "Avadel" or "the Company," today announced that Greg Divis, Chief Operating Officer, and Mike Kanan, Chief Financial Officer, will present at the Deutsche Bank...

AVDL : 4.77 (-2.45%)
DB : 11.21 (+0.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade AVDL with:

Business Summary

Avadel Pharmaceuticals plc is a specialty pharmaceutical company. Its product pipeline consists of hospital and paediatrics. Hospital segment provides Bloxiverz(R), Vazculep(R) and Akovaz(TM). Paediatrics segment provides Karbinal (TM) ER, AcipHex(R) Sprinkle and Flexichamber(TM). The company operates...

See More

Key Turning Points

2nd Resistance Point 5.10
1st Resistance Point 4.93
Last Price 4.77
1st Support Level 4.66
2nd Support Level 4.56

See More

52-Week High 11.93
Fibonacci 61.8% 9.15
Fibonacci 50% 8.30
Fibonacci 38.2% 7.44
Last Price 4.77
52-Week Low 4.66

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar